LEXINGTON, Mass.--(BUSINESS WIRE)--Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today announced the closing of a $179 million underwritten public offering of 3.16 million shares of common stock, including 412,500 shares of common stock that were issued pursuant to the exercise of the underwriters’ option to purchase additional shares, at a price of $56.63 per share.
Help employers find you! Check out all the jobs and post your resume.
